These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1746075)

  • 21. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
    Daskivich TJ; Oh WK
    Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
    Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
    Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
    Williams G; Lindsay S; Bowsher WG
    Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monthly dosage form of leuprolide approved by FDA.
    Oncology (Williston Park); 1989 Apr; 3(4):139. PubMed ID: 2518158
    [No Abstract]   [Full Text] [Related]  

  • 28. [Results of long-term follow-up in treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enantone-Gyn monthly depot)].
    Regidor PA; Schindler AE; Bühler K; Gerhard I; Kimmig R; Meinen K; Hoffmann G; Lübben G; Kienle E
    Zentralbl Gynakol; 1996; 118(5):283-90. PubMed ID: 8701625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemical andropause and amyloid-beta peptide.
    Gandy S; Almeida OP; Fonte J; Lim D; Waterrus A; Spry N; Flicker L; Martins RN
    JAMA; 2001 May; 285(17):2195-6. PubMed ID: 11325319
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).
    Isurugi K; Niijima T; Akaza H; Aso Y; Koiso K; Fuse M; Okada K; Usami M; Ohashi T; Ueda T;
    J Chemother; 1989 Jul; 1(4 Suppl):1237-41. PubMed ID: 16312848
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
    Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
    Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical evaluation of enantone in the treatment of prostate cancer].
    Zhang L; Tao D; Wang S
    Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):218-20. PubMed ID: 10920902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
    Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
    Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
    Pollack A; Horwitz EM
    Nat Clin Pract Oncol; 2005 Jan; 2(1):12-3. PubMed ID: 16264846
    [No Abstract]   [Full Text] [Related]  

  • 37. Injection systems for two luteinising hormone-releasing hormone agonists: a comparative assessment of administration times and nurses' perceptions.
    Morgan G; Cooley C
    Eur J Oncol Nurs; 2005 Dec; 9(4):334-40. PubMed ID: 16298160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Novel intermittent GnRHa therapy for patients with endometriosis].
    Tanaka T; Umesaki N
    Nihon Rinsho; 2001 Jan; 59 Suppl 1():124-8. PubMed ID: 11235149
    [No Abstract]   [Full Text] [Related]  

  • 39. A new PTP parameter as potential predictor of prostate cancer response to therapy.
    Tarle M
    Int J Rad Appl Instrum B; 1988; 15(2):225-7. PubMed ID: 3366623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new injectable liquid crystal system for one month delivery of leuprolide.
    Ki MH; Lim JL; Ko JY; Park SH; Kim JE; Cho HJ; Park ES; Kim DD
    J Control Release; 2014 Jul; 185():62-70. PubMed ID: 24794897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.